The use of cord blood units (CBU) as a source of hematopoietic stem cells (HSC) for transplant has increased during the last few years. 1 The main obstacle for the use of CB for adult transplantation is the proportionally small content of HSC, which leads to delayed engraftment, relatively slower immunological recovery and higher incidence of graft failure when compared with other HSC sources. The end result is a higher incidence of TRM secondary to infections. 1, 2 Mycobacterial tuberculosis (MT) infections are rare among hematopoietic SCT (HSCT) patients, but are more likely to affect patients from countries with high incidence and prevalence of tuberculosis. [3] [4] [5] [6] [7] Here, we discuss a case of MT in a CB transplant recipient coming from an MT endemic area, and who received his transplant in the United States.
A 19-year-old male Brazilian patient was diagnosed with nodular sclerosis Hodgkin's lymphoma, clinical stage III-B, in August 2002. He was initially given three cycles of ABVD (adriamycin, bleomycin, vimblastin and dacarbazine), with partial response, followed by disease progression. After November 2002, salvage therapy with three cycles of EPOCH (CY, etoposide, vincristine, doxorubicin and prednisone) was administered, with stabilization of disease. This minor response was consolidated with highdose therapy (CY 120 mg/kg and TBI of 1200 cGy ) and autologous HSCT rescue in February 2003; a CR was then obtained.
In On day þ 194, he developed limited chronic GVHD of the skin managed with tacrolimus and topical steroids. One year after transplant, the diagnosis of chronic extensive GVHD involving mouth and skin was performed. Treatment with mycophenolate mofetil led to complete resolution of the complication. All the immunosuppressants were withdrawn on August 2007. No signs of Hodgkin's disease were present and the patient went on to graduate in Law School.
In December 2007, he presented in Brazil with chest and back pain. Positron emission computed tomography (system Discovery ST, GE Medical Systems, Piscataway, NJ, USA) showed a lesion with increased fluorodeoxyglucose uptake in the paravertebral region involving the second, third and fourth thoracic vertebrae, with evidence of a large abscess (Figure 1a) .
Fine-needle aspiration of the abscess was performed and the fluid submitted for microbiologic studies and cultures. PCR for MT was positive and confirmed by a culture 4 weeks later.
The patient was started on rifampicin (600 mg/day), isoniazid (400 mg/day), pyrazinamide (2000 mg/day) and ethambutol (1200 mg/day). After 1 month, when the tuberculosis antibiogram became available, ethambutol was suspended. The patient had good response with the antibiotics and the follow-up magnetic resonance imaging (Signa HDxt 1.5T, GE Medical Systems) showed a remarkable decrease in the paravertebral lesion (Figure 1b) . Pyrazinamide was discontinued after 2 months, and the patient is now asymptomatic undergoing treatment with rifampicin and isoniazid.
The incidence of MT among HSCT recipients is variable, ranging from 0.6 to 9.7%. Several transplant-related factors are associated with this infection, such as the development of GVHD, graft T-cell depletion and the use of mismatched donors. However, the most important risk factor is the incidence of MT infection in the normal population, as the majority of MT infections in HSCT recipients are due to the reactivation of primary infection. [3] [4] [5] [6] [7] The patient presented here came from an MT endemic area in Brazil, where 46.6 new cases are diagnosed per 100 000 inhabitants. This number can be actually higher because there has been estimated around 30% of the subnotification of tuberculosis in Brazil. 9 Other authors have reported relatively high incidence of MT in HSCT recipients from different endemic areas in China, Saudi Arabia and India. 3, 4, 6 The exact influence of donor type and graft composition in MT infection post-HSCT is not known, but a recent retrospective analysis of the European group has documented a higher incidence of infection among patients receiving T-cell-depleted grafts, probably because of the slower immunological reconstitution. 10 The incidence of MT infection among CBU transplant recipients is also not known. There is only one report showing four clinical cases of systemic infection during the first 100 days after HSCT.
11 Interestingly, our patient developed MT infection 3 years after transplant, when off immunosuppressants and without GVHD. We can speculate that normal quantitative immunological tests may not represent the real immunological status that might be qualitatively compromised, especially in the patient presented here.
A definitive diagnosis of MT in patients who are submitted to HSCT is usually difficult to establish, given immunological deficits that may lead to a mild and nonspecific clinical picture. The presence of fever, cough, chest pain and pulmonary infiltrates are frequent and nonspecific findings of MT infection. Usually, there is no typical granuloma formation, and MT infection should be always one of the differential diagnoses in high-risk patients from endemic areas. [3] [4] [5] [6] [7] 10, 11 The use of chemoprophylaxis should also be considered in patients with documented earlier exposure to MT. 
